Related Experiment Videos
Prostaglandin E2 regulation of tumoristatic factor production by macrophage-like P388D1 cells
Abstract:
Macrophage-like P388D1 cells, when stimulated with lipopolysaccharide (LPS), produced a factor(s) whose activity was inhibitory to growth of Lewis lung carcinoma cells. Indomethacin, a prostaglandin-synthesis inhibitor, augmented the production of tumoristatic activity by LPS-stimulated P388D1 cells, whereas exogenous prostaglandin E2 (PGE2) suppressed its secretion. These results suggest that P388D1 cells regulate their antitumor abilities by producing PGE2, which inhibits production of soluble factor(s) with tumoristatic activities.
Insights
Lipopolysaccharide (LPS) stimulates macrophages to produce tumor-inhibiting factors. However, prostaglandin E2 (PGE2) production by these cells suppresses this crucial anti-cancer activity.
Area of Science:
- Immunology
- Cancer Biology
- Cell Biology
Background:
- Macrophage-like P388D1 cells are involved in immune responses.
- Lipopolysaccharide (LPS) is a known stimulator of immune cells.
- Lewis lung carcinoma is a model for cancer research.
Purpose of the Study:
- To investigate the interaction between P388D1 cells, LPS, and tumor growth.
- To elucidate the role of prostaglandin E2 (PGE2) in macrophage-mediated anti-tumor activity.
Main Methods:
- Stimulation of P388D1 cells with LPS.
- Assessment of the production of growth inhibitory factors.
- Use of indomethacin (prostaglandin-synthesis inhibitor) and exogenous PGE2 to modulate activity.
Main Results:
- LPS-stimulated P388D1 cells produced factors inhibitory to Lewis lung carcinoma cell growth.
- Indomethacin enhanced this tumoristatic activity.
- Exogenous PGE2 suppressed the secretion of these tumoristatic factors.
Conclusions:
- P388D1 cells regulate their anti-tumor capacity through PGE2 production.
- PGE2 acts as a negative feedback mechanism, inhibiting the secretion of tumoristatic factors by macrophages.